| Chapter title |
Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development.
|
|---|---|
| Chapter number | 1 |
| Book title |
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
|
| Published in |
Advances in experimental medicine and biology, December 2015
|
| DOI | 10.1007/978-3-319-24932-2_1 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-924931-5, 978-3-31-924932-2
|
| Authors |
Priyanga Wijesinghe Ph.D., Aliccia Bollig-Fischer Ph.D., Priyanga Wijesinghe, Aliccia Bollig-Fischer |
| Editors |
Aamir Ahmad, Shirish M. Gadgeel |
| Abstract |
Lung cancer is the leading cause of cancer-related deaths in the United States and the 5-year overall survival outlook for a patient has not improved in several decades. Recently, however, molecular and genomic profiling of the lung tumors has revealed recurring somatic mutations. As a result the therapeutic landscape of lung cancer is undergoing a paradigm shift from a purely histology-based understanding of the disease to subtype distinctions based on tumor genetics, which has launched cancer-specific, mechanism-based targeted therapies with clear benefit to patients. While targeted therapy advancements are being made at an ever increasing rate, a new challenge in the form of drug resistance has also emerged. This review summarizes the current literature for these issues. |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 9 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 22% |
| Student > Bachelor | 2 | 22% |
| Lecturer > Senior Lecturer | 1 | 11% |
| Student > Ph. D. Student | 1 | 11% |
| Student > Postgraduate | 1 | 11% |
| Other | 0 | 0% |
| Unknown | 2 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 44% |
| Biochemistry, Genetics and Molecular Biology | 3 | 33% |
| Unknown | 2 | 22% |